Pharming Group N.V.

Report Publication Announcement • Mar 8, 2012

PHARMING TO PRESENT AT ROTH GROWTH CONFERENCE ON MARCH 12, 2012

Leiden, The Netherlands, March 8, 2012. Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) today announced that Sijmen de Vries, Chief Executive Officer, will present at the following investment conference:

Roth Capital Partners 24th Annual Growth Stock Conference on Monday, March 12, 2012, at 3:00 p.m. pacific time (midnight Central European Time) in Dana Point, California, US.

A webcasts of this presentation will be available during the event at the 'Investor Relations' section of www.pharming.com and will be archived and available on the website for 14 days.

About Roth Capital Partners Annual Growth Stock Conference

ROTH's annual three-day conference brings together executives from over 400 growth companies and 1,000+ investors from the buy side. The event is designed to provide investors with a unique opportunity to gain insight into small and midcap growth companies across a variety of sectors, including healthcare. ROTH combines company presentations, Q&A sessions, expert panels and management one-on-one meetings to provide institutional clients with extensive interaction with senior management to gain in-depth insights into each company.

About Pharming Group NV

Pharming Group NV is developing innovative products for the treatment of unmet medical needs. RUCONEST® (RHUCIN® in non-European territories) is a recombinant human C1 inhibitor approved for the treatment of angioedema attacks in patients with HAE in all 27 EU countries plus Norway, Iceland and Liechtenstein, and is distributed in the EU by Swedish Orphan Biovitrum (OMX: SOBI). RHUCIN® is partnered with Santarus, Inc (NASDAQ: SNTS) in North America where the drug is undergoing Phase III clinical development. The product is also being evaluated for follow-on indications in the area of reperfusion injury related diseases. The advanced technologies of the Company include innovative and validated platforms for the production of protein therapeutics, technology and processes for the purification and formulation of these products. Recently a new project, using the validated transgenic rabbit platform, aimed at the development of recombinant Factor VIII for the treatment of Haemophilia A was initiated was initiated by partner, Renova Life, Inc. Additional information is available on the Pharming website, www.pharming.com.

This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements.

Contact

Sijmen de Vries, CEO: T: +31 (0)71 524 7400 Karl Keegan, CFO: T: +31 (0)71 524 7400

FTI Consulting Julia Phillips/ John Dineen, T: +44 (0)207 269 7193